Bionano Genomics Inc BNGO

NAS: BNGO | ISIN: US09075F1075   15/05/2024
1,150 USD (+3,60%)
(+3,60%)   15/05/2024

15 maart 2021 · Bionano Genomics to Present at Several Upcoming Investor Conferences · Persbericht

10 maart 2021 · Bionano Genomics Presented at H.C. Wainwright Global Life Sciences Conference · Persbericht

9 maart 2021 · Bionano Genomics to Report Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call and Webcast on March 23rd, 2021 · Persbericht

3 maart 2021 · Bionano Customer Praxis Genomics Receives DEX Z-Codes from Palmetto for their Whole Genome Analysis LDT on Saphyr · Persbericht

2 maart 2021 · Bionano Genomics to Present at the Cowen 41st Annual Health Care Conference · Persbericht

1 maart 2021 · Bionano to be Featured at AGBT 2021 with Presentations of Scientific Discoveries made with Saphyr in Psychiatric Disorders and Cancer · Persbericht

25 februari 2021 · Bionano’s Saphyr Data Prove Essential in Creating the Most Comprehensive, Ethnically Diverse Collection of Genome Variation Ever Completed · Persbericht

11 februari 2021 · Bionano Genomics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference · Persbericht

5 februari 2021 · Presentation Recordings from Bionano’s Next-Generation Cytogenomics Symposium, its Most Attended Event to Date, Now Available Online · Persbericht

29 januari 2021 · Dr. Gordana Raca from Children’s Hospital Los Angeles Presents Findings That Show Saphyr Detects Druggable Gene Fusions in Pediatric Acute Leukemias that NGS and Cytogenetics Missed · Persbericht

25 januari 2021 · Bionano Genomics Announces Closing of $230 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares · Persbericht

20 januari 2021 · Bionano Genomics Announces Pricing of $200 Million Underwritten Public Offering of Common Stock · Persbericht

19 januari 2021 · Bionano Genomics Announces Proposed Underwritten Public Offering of Common Stock · Persbericht

19 januari 2021 · Day Five of Bionano’s Next-Generation Cytogenomics Symposium: Saphyr Identifies Structural Variants that May Predispose to Severe COVID-19 Illness · Persbericht

14 januari 2021 · Day Three of Bionano’s Next-Generation Cytogenomics Symposium: Saphyr Provides Complete Structural Variation Analysis in Solid Tumors, Enables Discovery of Novel Diagnostic Markers and Drug Targets · Persbericht

13 januari 2021 · Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement · Persbericht

13 januari 2021 · Day Two of Bionano’s Next-Generation Cytogenomics Symposium: Saphyr Outperforms Standard Cytogenetics in Heme Malignancies, is Less Expensive, Provides Actionable Information Faster, in Single Assay · Persbericht

12 januari 2021 · Bionano Genomics Announces Closing of $101.8 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares · Persbericht

11 januari 2021 · COVID-19 Host Genome SV Consortium Identifies Structural Variants with Possible Roles in Pathogenesis and Outcomes in Severely Ill COVID-19 Patients Using Bionano’s Saphyr® System · Persbericht

11 januari 2021 · Bionano Genomics Announces the Kick-Off of its Next-Generation Cytogenomics Symposium, The Largest Event Yet to Showcase Saphyr’s Utility in Genome Analysis for Genetic Disease and Cancer · Persbericht

Mijn selecties